As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

The optimal hydroxychloroquine blood level in lupus is between 750 ng/mL and 1,150 ng/mL, which can help prevent active ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Women’s cardiovascular health has long been overlooked and understudied. Here are some things to keep in mind.

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

Systemic Lupus Erythematosus is one of the most complex autoimmune diseases seen in modern medicine, affecting multiple organs and presenting differently from one patient to another. Often referred to ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

USA: Researchers have reported that low vitamin D levels are strongly linked to a higher risk of death and cardiovascular ...